pirenzepine has been researched along with Amyloid Angiopathy, Cerebral in 1 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Paganetti, P | 1 |
| Antoniello, K | 1 |
| Devraj, K | 1 |
| Toni, N | 1 |
| Kieran, D | 1 |
| Madani, R | 1 |
| Pihlgren, M | 1 |
| Adolfsson, O | 1 |
| Froestl, W | 1 |
| Schrattenholz, A | 1 |
| Liebner, S | 1 |
| Havas, D | 1 |
| Windisch, M | 1 |
| Cirrito, JR | 1 |
| Pfeifer, A | 1 |
| Muhs, A | 1 |
1 other study available for pirenzepine and Amyloid Angiopathy, Cerebral
| Article | Year |
|---|---|
Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis.
Topics: Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cerebral Amyloid Angiopathy; Disease Models, An | 2014 |